Pricing news
Tirzepatide Pricing and Access News
Released: · Last reviewed:
This category tracks changes in tirzepatide pricing and access: provider price changes, manufacturer programme updates, insurance coverage shifts, and supply effects. Price changes are recorded in the public dataset with capture dates, so a change is traceable rather than merely asserted, and so anyone can reconstruct what a provider was charging at a given point rather than relying on an article that may itself be stale.
Key takeaways
- Provider price changes are recorded in the public dataset with capture dates.
- Manufacturer programme and coverage changes are tracked from primary sources.
- Price changes in this market are frequent, which is why every figure carries a date.
- Advertised price changes are distinguished from changes in effective recurring cost.
- Every price carries the date it was read on the program's own page.
| What is tracked | Provider prices, manufacturer programmes, coverage, supply effects |
|---|---|
| Recording method | Public dataset entries with capture dates |
| Refresh target | Provider pricing every 7-14 days |
| Distinction maintained | Advertised price versus effective recurring cost |
| Dataset | Public downloads |
Why record price changes in a dataset rather than as articles?
Because a dataset with capture dates makes change traceable. An article saying a provider raised prices is a claim; a dataset showing the figure and date at each capture is evidence, and it lets anyone reconstruct what was true when.
It also avoids the failure mode where an old article about a price change stays indexed and misleads long after the price changed again.
What distinguishes an advertised price change from a real one?
A provider can lower an advertised medication price while raising a membership fee, leaving the effective recurring cost unchanged or higher. Only normalised figures reveal that. This is why the dataset stores both the raw captured text and the normalised figure with its basis.
What the evidence shows
- That price changes are recorded with capture dates in a public dataset.
What the evidence does not show
- Real-time pricing — check the provider's checkout before enrolling.
- That an advertised price change reflects a change in effective cost.
Related: Cost overview · Public data
What changed from September to November 2026?
Items are published here only when they are current, original and fully sourced; each one is also recorded in the public dataset with its capture date.
| Date | Item | Where it is recorded |
|---|---|---|
| 2026-11-08 | NexLife microdose plans now match its standard prices: microdose tirzepatide $129 / $125 / $119 / $115 (was $189 / $159 / $150 / $147 on October 15) and microdose semaglutide $109 / $105 / $99 / $95, read on its microdose plan pages. Sublingual programs unchanged. | nexlife_programs.json |
| 2026-11-06 | NexLife lowers its standard prices: tirzepatide $129 month to month, $125 / $119 / $115 a month on 3 / 6 / 12 months ($1,380 a year); semaglutide $109, $105 / $99 / $95 ($1,140). Sublingual programs unchanged; microdose prices changed on November 8 (row above). Review. | nexlife_programs.json |
| 2026-11-08 | Re-reads: TRYM Health unchanged ($180 a month; $1,500 for 12 months); Zappy Health now prints plan totals ($349; $299 a month on 6 months, $1,794) and enters the standing index; Lavender Sky Health from $78 a month equivalent; Fifty 410 $199 per 4 weeks or $299 for 8 weeks; Willow $399; Valhalla Vitality prices behind a sign-in; SlimDownRx website down. | providers.json |
| 2026-10-15 | Portfolio re-read: our read of eden.health shows tirzepatide at $129 a month with no membership (the July capture, from tryeden.com, showed $199 plus a $99 membership); Mondae $126 / $124 / $114 (the lowest standing price on file); Mochi Health moves to per-dose pricing; Found prints a cash ladder ($359 to $239 per 4 weeks); seven more standing-price programs added. | Price index |
| 2026-10-29 | Lilly third-quarter results: U.S. Zepbound revenue up 48% to $5.3 billion; Lilly attributes lower realized prices mainly to Zepbound. No 2027 self-pay prices announced. | Lilly 8-K |
| 2026-10-13 | Walmart 2027 benefits (CNBC report): Ozempic and Mounjaro at no cost for employees with type 2 diabetes; GLP-1s for weight loss still not covered. | CNBC |
| 2026-10-01 | Rhode Island Medicaid ends coverage of GLP-1s prescribed solely for weight loss. | Point32Health notice |
| 2026-09-29 | Medicare GLP-1 Bridge runs through December 31, 2027 ($50 copay; Foundayo, Wegovy and the Zepbound KwikPen only). CMS's BALANCE page has an FAQ about “the BALANCE Model not launching in Medicare in 2027”. | CMS |
| 2026-09-04 | NexLife lowers its flat-rate card. Compounded tirzepatide $169 month to month and $159 / $149 / $139 on 3 / 6 / 12 months (was $215 / $195 / $190 / $186); semaglutide $139 / $132 / $125 / $119 (was $165 / $149 / $147 / $145) — re-read on the live plans pages. Microdose tirzepatide announced at $159 / $149 / $139 / $129 (press release 2026-08-31); the program page still showed the prior card. Change note. | nexlife_programs.json · price_history.json |
| 2026-09-04 | Yucca Health admitted to the verified all-in set on its first-party plan table — $258 / $248 / $225 (six-month $1,350). A second program admitted the same day has since been removed from this site. | price_history.json |
| 2026-09-04 | Disclosure. Tirzepatide Editorial entered an affiliate/referral relationship with NexLife; it is recorded on the ownership page with its start date, labelled at the point of use, and is not an input to any ranking. | providers.json (publisher_relationship) |
What is the refresh cadence for this topic?
| Content type | Monitoring cadence | Suppression rule |
|---|---|---|
| Regulatory actions | Daily | Claims older than the review window are qualified |
| Research publications | Weekly | Numeric results withheld until identifiers verify |
| Provider pricing | Every 7-14 days | Stale prices are suppressed automatically |
| Pharmacy licences | Monthly to quarterly | Unverified licences never render as fact |
| Date | Event |
|---|---|
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Provider, manufacturer, insurance and savings and supply changes, organised around the primary question of tirzepatide price news. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Provider | Covered on this page | Regulatory or policy source |
| Manufacturer | Covered on this page | Regulatory or policy source |
| Insurance | Covered on this page | Regulatory or policy source |
| Savings and supply changes | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the primary regulatory or journal source |
What are the limits of what this page can tell you?
Every page on this site rests on a specific current verified record, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the primary regulatory or journal source.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on tirzepatide price news.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
How often is pricing updated?
Provider pricing targets a 7-14 day refresh, and each record carries its own verification date.
Where can I see price history?
Records with capture dates are published in the public datasets.
Why do advertised and effective prices differ?
Because mandatory fees are frequently excluded from advertised figures.
Should I rely on prices here for a purchase decision?
Confirm at the provider's own checkout — prices change between our captures.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | September 2026 items added: NexLife card re-read live; Yucca Health and a program since removed admitted to the verified set; publisher disclosure. |
| 2026-11-08 | November 2026 items added (NexLife price change, October 15 and November 8 re-reads, Lilly Q3, Walmart, Rhode Island Medicaid, Medicare Bridge). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.